SearchDictionaryMobileLogin Register FREE

sibrafiban

Subscribe to Selected New Research on sibrafiban
20  relevant articles (0 outcomes, 14 trials/studies) found for this Bio-Agent

Description: prodrug of Ro-44-3888; structure in first source

Also Known As:
((1-(2-((4-(amino(hydroxyimino)methyl)benzoyl)amino)-1-oxopropyl)-4-piperidinyl)oxy)acetic acid ethyl ester; Ro 48-3657; Ro-48-3657

Bio-Agent Context: Research Results

-
Organic Chemicals: 40
-
Amines: 1233
-
Hydroxylamines: 11
-
Oximes: 229
*
sibrafiban: 20
-
Heterocyclic Compounds: 23
-
1-Ring Heterocyclic Compounds
-
Piperidines: 7
*
sibrafiban: 20

Experts

1. Armstrong, Paul W: 2 articles (08/2007 - 12/2005)
2. Newby, L Kristin: 2 articles (08/2007 - 12/2005)
3. Hochman, Judith S: 1 article (08/2007)
4. Bhapker, Manju V: 1 article (08/2007)
5. Wong, Cheuk-Kit: 1 article (08/2007)
6. Aylward, Phil E: 1 article (08/2007)
7. Califf, Robert M: 1 article (08/2007)
8. Pfisterer, Matthias: 1 article (08/2007)
9. White, Harvey D: 1 article (08/2007)
10. Van de Werf, Frans: 1 article (08/2007)

Related Diseases

1. Acute Coronary Syndrome
07/01/1999 - "Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered IIb/IIIa antagonist, in patients with acute coronary syndrome."
02/03/1998 - "METHODS AND RESULTS: The Thrombolysis in Myocardial Infarction (TIMI) 12 trial was a phase II, double-blind, dose-ranging trial designed to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of sibrafiban in 329 patients after acute coronary syndromes"
10/01/2004 - "METHODS: To examine the prevalence of HRT use and relationships with intermediate-term outcomes among women with ACS, we classified as HRT users or nonusers 4029 postmenopausal women (age > 50 years or postmenopausal by case report form) randomized in the Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-Acute Coronary Syndromes (SYMPHONY) and 2nd SYMPHONY trials"
06/05/2002 - "METHODS: In a prospective substudy of the Sibrafiban Versus Aspirin to Yield Maximum Protection From Ischemic Heart Events Post-acute Coronary Syndromes (SYMPHONY) trials, which randomized patients with acute coronary syndromes (ACS) to receive aspirin or sibrafiban, we measured cTnI (positive, > or =1.5 ng/ml) and CK-MB (positive, > or =7 ng/ml) in 481 patients with PCI"
04/03/2001 - "BACKGROUND: The first Sibrafiban Versus Aspirin to Yield Maximum Protection From Ischemic Heart Events Post-Acute Coronary Syndromes (SYMPHONY) trial showed no benefit of 2 doses of sibrafiban over aspirin for secondary prevention after acute coronary syndromes"
Get all the results and reference details, order at left...
2. Syndrome
07/01/1999 - "Pharmacokinetics (PK) and pharmacodynamics (PD) of oral sibrafiban and its metabolites were evaluated in patients postacute coronary syndrome receiving once- or twice-daily sibrafiban for up to 28 days at several dose levels"
08/01/2007 - "METHODS: Among the 15,904 patients from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) and second SYMPHONY trials, we examined the rates of use of EBM according to age (< 75 or > or = 75 years, and 3 subgroups of 5 year increments among patients > or = 75 years)"
08/01/2007 - "Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials."
12/01/2005 - "Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical trials."
09/01/2005 - "SUBJECTS AND METHODS: Using 15 071 patients (normal weight [BMI = 18.5-24.9 kg/m(2)], overweight [BMI = 25-29.9 kg/m(2)], obese [BMI = 30-34.9 kg/m(2)] or very obese [BMI > or =35 kg/m(2)]) randomized from 1997-1999 in the SYMPHONY (Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes) and 2nd SYMPHONY trials, we evaluated the relationships between BMI and 30-day, 90-day, and 1-year mortality and 30-day and 90-day death or myocardial infarction"
Get all the results and reference details, order at left...
3. Myocardial Infarction
4. Stroke (Strokes)
5. Thrombosis (Thrombus)
12 Diseases and 20 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1. Aspirin (Acetylsalicylic Acid)
2. Glycoproteins (Glycoprotein)
3. Platelet Membrane Glycoprotein IIb
4. M-2 protocol (M 2)
5. tetrachloroisophthalonitrile (Bravo)
6. orbofiban
7. MB Form Creatine Kinase
8. Troponin T (T, Troponin)
9. Ticlopidine (Ticlid)
10. Phosphotransferases (Kinase)
18 Drugs and Important Bio-Agents and 17 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1. Stents
1 Therapies and Procedures and 1 more articles analyzed in the Research Interface, order at left...

Research Interface

 

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.
  • Unlimited Disease, Drug and Therapy Search
  • 2 clicks from Disease to Drug to Evidence
  • Trial References
  • All the Positive Outcomes
  • Detailed Relationship Timeline Charts
  • Full Article Reference Details
  • Includes Mobile Interface Subscription
  • One-click to FDA Products/Patents
  • Request Institution License details >>
Price:$490.00 access via web interface, 1 year subscription
Proceed to Checkout >>
Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.
  • Access from any web enabled PDA or Phone
  • Trial references
  • All the Positive Outcomes
  • Drug and Therapy searches
  • Full Article Reference Details
  • Try Mobile Interface >>
Price:$45.00 access via "curehunter.com/m", 1 year subscription
Proceed to Checkout >>